Whole Foods Market, Inc. (WFM) had a light trading with around 2.94M shares changing hands compared to its three month average trading volume of 4.93M. The stock traded between $30.74 and $31.21 before closing at the price of $31.21 with 0.74% change on the day. The Austin Texas 78703 based company is currently trading 13.85% above its 52 week low of $27.67 and -11.08% below its 52 week high of $35.58. Both the RSI indicator and target price of 54.01 and $29.94 respectively, lead us to believe that it should be put on hold over the coming weeks.
Whole Foods Market, Inc. operates natural and organic foods supermarkets. Its stores offers produce, packaged goods, bulk, frozen, dairy, meat, bakery, prepared foods, coffee, tea, beer, wine, cheese, nutritional supplements, vitamins, body care, pet foods, and household goods. As of November 2, 2016, the company operated 464 stores in the United States, Canada, and the United Kingdom. Whole Foods Market, Inc. was founded in 1978 and is headquartered in Austin, Texas.
E*TRADE Financial Corporation (ETFC) managed to rebound with the stock climbing 1.68% or $0.6 to close the day at $36.37 on light trading volume of 2.93M shares, compared to its three month average trading volume of 3.15M. The New York New York 10020 based company has been outperforming the investment brokerage – national group over the past 52 weeks, with the stock gaining 46.59%, compared to the industry which has advanced 48.35% over the same period. With RSI of 57.54, the stock should still continue to rise and get closer to its one year target estimate of $39.59, making it a hold for now.
E*TRADE Financial Corporation, a financial services company, provides brokerage and related products and services primarily to individual retail investors under the E*TRADE Financial brand name. It operates through two segments, Trading and Investing, and Balance Sheet Management. The Trading and Investing segment offers retail brokerage products and services, investor-focused banking products, and corporate services. The Balance Sheet Management segment manages asset allocation; loans previously originated by the company or purchased from third parties; deposits and customer payables; and credit, liquidity, and interest rate risk. The company provides its services to customers through digital platforms; and a network of customer service representatives and financial consultants through phone, email, and online at two branches, as well as in person through 30 branches across the United States. E*TRADE Financial Corporation was incorporated in 1982 and is headquartered in New York, New York.
Opko Health, Inc. (OPK) shares were up in last trading by 0.56% to $8.98. It experienced lighter than average volume on day. The stock decreased in value by almost -4.16% over the past week and fell -24.54% in the past month. It is currently trading -13.82% below its 50 day moving average and -11.11% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -26.09% decrease in value from its one year high of $12.15. The RSI indicator value of 33.32, lead us to believe that it is a hold for now.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States, Ireland, Chile, Spain, Israel, and Mexico. Its diagnostics business operates Bio-Reference Laboratories, a clinical laboratory that offers comprehensive laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, womens health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units. The Bio-Reference Laboratories also provides core genetic testing and leverages products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment features Rayaldee, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D deficiency and VARUBI for chemotherapy-induced nausea and vomiting. Its biologics business engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product under development for the treatment of growth hormone deficiency, and developing Factor VIIa drug for hemophilia using the carboxl terminal peptide technology. The company was incorporated in 1991 and is headquartered in Miami, Florida.